Adaptive Biotechnologies (ADPT) Receivables (2018 - 2026)

Adaptive Biotechnologies has disclosed Receivables across 9 years of filings, most recently posting $49.9 million for Q1 2026.

• Receivables for Q1 2026 came in at $49.9 million, up 10.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $49.9 million (up 10.72% YoY), and the FY2025 annual result was $51.9 million, up 20.53% from the prior year.
• Receivables came in at $49.9 million for Q1 2026 at Adaptive Biotechnologies, down from $51.9 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $51.9 million in Q4 2025 to a low of $23.6 million in Q1 2022.
• The 5-year median for Receivables is $40.9 million (2022), against an average of $38.6 million.
• Across the five-year window, Receivables jumped 117.22% in 2022 and fell 4.62% in 2023, its largest moves.
• Adaptive Biotechnologies' Receivables stood at $40.9 million in 2022, then dropped by 4.62% to $39.0 million in 2023, then rose by 10.42% to $43.0 million in 2024, then advanced by 20.53% to $51.9 million in 2025, then decreased by 3.76% to $49.9 million in 2026.
• The last three Receivables figures came in at $49.9 million (Q1 2026), $51.9 million (Q4 2025), and $46.3 million (Q3 2025), per Business Quant data.